首页 | 本学科首页   官方微博 | 高级检索  
检索        

依巴斯汀联合多塞平治疗慢性荨麻疹的临床观察
引用本文:邹循辉,刘军麟,吴利辉.依巴斯汀联合多塞平治疗慢性荨麻疹的临床观察[J].中国热带医学,2013,13(3):365-366.
作者姓名:邹循辉  刘军麟  吴利辉
作者单位:1. 广东省惠州市皮肤病医院,广东惠州,516008
2. 海南省农垦总医院皮肤科,海南海口,570311
摘    要:目的评价依巴斯汀联合多塞平治疗慢性荨麻疹的疗效。方法采用随机开放平行对照的方法将100例慢性荨麻疹患者随机分成依巴斯汀、多塞平联合治疗组和单纯依巴斯汀治疗组,分别予依巴斯汀10mg联合多塞平25mg和单纯依巴斯汀治疗,均每日1次口服,观察第28d的疗效及停药1周后的复发率。结果治疗28d后两组有效率分别为96%、74%,两组差异具有显著性(χ2=3.45,P〈0.05)。停药1周后的复发率,治疗组为24%,显著低于对照组的46%(χ2=4.32,P〈0.05)。结论依巴斯汀联合多塞平治疗慢性特发性荨麻疹疗效高,复发率低,值得临床推广。

关 键 词:慢性荨麻疹  依巴斯订  多塞平  疗效

Clinical observation on efficacy of ebastine combined with doxepin and ebastine alone in treatment of chronic urticaria patients
ZOU Xun-hui,LIU Jun-lin,WU Li-hui.Clinical observation on efficacy of ebastine combined with doxepin and ebastine alone in treatment of chronic urticaria patients[J].China Tropical Medicine,2013,13(3):365-366.
Authors:ZOU Xun-hui  LIU Jun-lin  WU Li-hui
Institution:1. Huizhou Municipal Dermatosis Hosptial,Huizhou 516008, Guagndong; 2. Department of Dermatosis of Hainan Nongken General Hospital,Haikou 570311,Hainan,P. R.China)
Abstract:Objective To evaluate the efficacy of ebastine combined with doxepin in treatment of chronic urticaria.Methods A randomized clinical trial on 100 patients was conducted.The patients were divided randomly into ebastine combined with doxepin group(study group)and ebastine group(control group),The patients in study group were treated with daily ebasdine 10mg combined with doxepin 25mg and those in the control group were treated with ebasdine 10mg alone.The recurrent rates were also recorded 4 weeks after discontinuation of the treatment.Results The effective rate of study group and control group were 96.0% and 75% respectively without showing significant difference between the two groups(X=3.45,P0.05).Conclusions The efficacy of bbasdine combined with doxepin is high in treatment of chronic urticaria with low recurrent rate.
Keywords:Chronic urticaria  Ebastine  Doxepin  Therapeutic effevt
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号